We presented substantial evidence demonstrating the capacity of GLP-1RAs to alleviate experimental colitis by inhibiting pro-inflammatory signalling pathways through the downregulation of the PI3K/AKT, NFκB, and CREB/PKA dependent signalling pathways. This evidence concerns the gene AKT1 and colitis.